NantWorks

18 articles about NantWorks

• 

  Biotechs Developing Innovative Ways to Activate the Immune System Against COV...

  12/8/2020

  BioSpace spoke with a few companies that have some ingenious ideas at different stages of preclinical and clinical development.

• NantOmics to Present Results of DESMOPAZ Study from French Sarcoma Group (FSG) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC will present findings on how pazopanib (PZ) has meaningful clinical activity in patients with progressive desmoid tumors (DT) during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Share Results of NantOmics Pharmacogenomics Test at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC, will present results from the NantOmics pharmacogenomics test, an integrative panomic approach to pharmacogenomics screening, during the developmental therapeutics session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Present Potential Treatment Options for SCLC Patients with Multiplexed Clinical Proteomic Testing at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC will present findings on potential treatment options for small-cell lung cancer (SCLC) patients with multiplexed clinical proteomic testing during the lung cancer.

• NantHealth and NantOmics to Present Patterns of Immune Checkpoint Molecules in Relation to PD-L1 Expression at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantHealth, Inc., and NantOmics, LLC will present findings on how targeting immune checkpoints and employing combinations has led to clinical benefit across a variety of tumor types during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantHealth and NantOmics to Present Data on the Frequency of Non-Expressed Variants Tested by Standard NGS Panel at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantHealth, Inc. and NantOmics, LLC will present findings on how 17 percent of next generation sequencing (NGS) 50 gene panel variants are not expressed in RNA sequencing during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Report Data on Cardiac Function in Sarcoma Patients Receiving Aldoxorubicin with Doxorubicin Equivalent Doses over 1000 mg/m2 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantOmics, LLC will present data on cardiac function in patients treated with aldoxorubicin in combination with Doxorubicin during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

• NantOmics to Present Data for Mutational Processes and Response to Neoadjuvant Chemotherapy in Breast Cancer at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on a genome-based investigation in the neoadjuvant GeparSepto trial for breast cancer treatment during the breast cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantOmics to Present Analysis on Potential Therapeutic Target in Adenoid Cystic Carcinoma at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantWorks, LLC announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present an analysis on how comprehensive molecular profiling with proteomic and genomic analysis revealed CDK6 as a potential therapeutic target in adenoid cystic carcinoma (ACC).

• NantHealth and NantOmics to Share Data on Next-Generation Sequencing of Paired DNA and RNA Analysis of Rare Tumors at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantHealth, Inc. and and NantOmics, will present data on next-generation sequencing of paired DNA and RNA analysis in patients with rare and ultra-rare cancers during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantHealth and NantOmics to Present Data on Three-Fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

  6/2/2018

  NantHealth and NantOmics will present data on three-fold overestimation of tumor mutation burden (TMB) using a 248 gene list as a panel to impute TMB during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

• NantWorks Release: NantOmics To Present Clinical Trial Data On The Characterization Of Molecular Profiles Of Metastatic Triple Negative Breast Cancer With GPS Cancer™ At ASCO 2017 Annual Meeting

  6/5/2017

• NantWorks Resolution Of "MOONSHOT"Trademark

  5/5/2017

• The World's Richest Doctor's New Cancer Vaccine and NantWorks's Science

  2/23/2017

• Benitec In-Licenses Clinical Program For Head And Neck Cancer From NantWorks

  12/27/2016

• NantWorks Release: Top Cancer Experts To Announce New England Initiative Combining Immuno-Oncology Clinical Trials And Molecular Science Through Genomics Supercomputing Infrastructure To Benefit Women And Pediatric Oncology Patients

  10/26/2016

• NantWorks Release: Top Cancer Experts To Announce New England Initiative Combining Immuno-Oncology Clinical Trials And Molecular Science Through Genomics Supercomputing Infrastructure To Benefit Women And Pediatric Oncology Patients

  10/25/2016

• People of Indiana Disappointed as World's Richest Doctor's NantWorks Will Not Expand at Old Pfizer Property

  9/14/2016